5 Insightful Analyst Questions From Quest's Q4 Earnings Call

Quest Diagnostics delivered a Q4 performance that exceeded Wall Street’s revenue and earnings expectations, prompting a positive market reaction. Management attributed this outcome to strong organic growth across physician, hospital, and consumer channels, with advanced diagnostics and recent partnerships like Fresenius Medical Care and Corewell Health contributing significant volume gains. CEO Jim Davis cited the company’s expansion in specialized testing—such as Alzheimer’s and autoimmune diagnostics—and collaborations that broadened geographic and health plan access as key drivers. Operational improvements, including automation and AI deployment, further supported productivity and customer experience gains.

Is now the time to buy DGX? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Quest’s Q4 Earnings Call

• Luke Sergott (Barclays) asked about core growth drivers for 2026, especially the consumer segment and new diagnostics. CEO Jim Davis pointed to strong growth in Alzheimer’s, autoimmune, and cardiovascular testing, as well as early momentum in consumer partnerships.
• Patrick Donnelly (Citi) pressed for clarity on margin impacts from new collaborations and Project Nova. CFO Sam Samad explained that while new business like Corewell adds revenue, its initial margins are low, but overall operating margin will still improve year over year.
• Michael Cherny (Leerink Partners) inquired about Quest’s competitive positioning and market share gains. Davis stated that recent network wins in key states and national coverage are fueling share gains versus hospital outreach and physician office labs.
• Tycho Peterson (Jefferies) sought updates on oncology test reimbursement and the commercial launch of new MRD tests. Davis detailed the progress with Medicare and commercial payers, emphasizing the speed and cost advantages of the new flow MRD test.
• Erin Wilson Wright (Morgan Stanley) focused on the sustainability and profitability of consumer testing. Davis and Samad highlighted recurring revenue from partnerships and noted direct-to-consumer testing carries above-average margins due to its cash-pay model.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely monitor (1) the ramp and margin progression of large-scale collaborations like Corewell and Fresenius, (2) sustained double-digit growth in consumer-initiated and advanced diagnostics testing, and (3) the impact of legislative developments, particularly around PAMA and the RESULTS Act, on reimbursement stability. The pace of operational efficiency gains from automation and AI initiatives will also be key.

Quest currently trades at $206.87, up from $191.25 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.